Health Blueprint

Back to Longevity News

News summary

Delix Therapeutics Closes Oversubscribed $100 Million Series C Financing to Advance Zalsupindole Into Phase II Development and Finance Broader Pipeline Advancement/Expansion

Source: BioSpace - Funding • Published: 10 Nov 2026, 00:49

Summarized by Masters of Longevity from BioSpace - Funding.

Delix closed a $100 million Series C to advance Zalsupindole and its neuroplastogen pipeline.

Delix Therapeutics Closes Oversubscribed $100 Million Series C Financing to Advance Zalsupindole Into Phase II Development and Finance Broader Pipeline Advancement/Expansion
Key Takeaways
  • The $100M round will fund Zalsupindole Phase IIb trials.
  • Phase Ib showed about a 50% mean MADRS score reduction.
  • The funding will expand neurodegeneration and other programs.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?